Standing on the corner

Who will protect us?

We came across FDA warning letters when reviewing regulatory documents for our Cochrane review on the influenza antivirals Tamiflu and Relenza. Specifically, a letter warned Roche, the manufacturer of Tamiflu, not to claim effects on complications such as pneumonia. This was interesting, as ameliorating or preventing complications were two of the most i…